Summary
India is fast emerging as the most preferred destination for clinical trials. Clinical trial is the final step in drug development process after preliminary laboratory research and animal testing. The process of drug discovery is quite long and expensive and trials for any drug are usually conducted in phases which might last for many years. Indian clinical trials market has witnessed tremendous growth with revenues from clinical trials expected to reach USD 500 mn by 2010.
The report provides a brief overview of the clinical trials market in India including market size, number of trials and phase-wise breakup of trials. Analysis of drivers reveals that low cost of trials, disease prevalence, sound medical infrastructure and adherence to international quality standards in India have made India an ideal destination for clinical trials. The key challenges identified include shortage of research professionals, lack of data exclusivity, delays in trial approval and instances of unethical trials in India. Government regulations outlines legal and regulatory framework for conduct of clinical trials in India
The competitive landscape identifies and profiles major Clinical Research organizations and Research Institutes taking part in clinical trials in India. The report also provides details of the private equity investments and key developments in Clinical Trials Market in India.
Table of Contents
Page 1: Executive Summary
Introduction
Page 2: Introduction
Market Overview
Page 3: Market Overview: Revenues from Clinical Trials, Number of Clinical Trials, Phase wise breakup of Clinical Trials
Drivers & Challenges
Page 4: Drivers and Challenges Summary
Page 5-8 Drivers
Page 9-10: Challenges
Government Regulations
Page 11: Guidelines and approval procedure for clinical trials
Page 12: Schedule Y of Drugs and Cosmetics Act
Page 13: ICMR guidelines
Competition
Page 14: Competition overview
Page 15-21: Clinical Research Organizations
Page 22-24: List of Institutes in Clinical Trials
PE Investments
Page 25: Key PE Investments
Key Developments
Page 26: Key Developments
